Luis Varela-Rodríguez1, Blanca Sánchez-Ramírez2, Verónica Ivonne Hernández-Ramírez1, Hugo Varela-Rodríguez3, Rodrigo Daniel Castellanos-Mijangos4, Carmen González-Horta2, Bibiana Chávez-Munguía1, Patricia Talamás-Rohana5. 1. Departamento de Infectómica y Patogénesis Molecular, CINVESTAV-IPN. Ave. Instituto Politécnico Nacional No. 2508, Col. San Pedro Zacatenco, C.P. 07360, Mexico City, Mexico. 2. Facultad de Ciencias Químicas, Universidad Autónoma de Chihuahua, Circuito 1, Nuevo Campus Universitario, C.P. 31125, Chihuahua, Chih, Mexico. 3. Laboratorio de Complejidad Molecular y Desarrollo, Unidad de Genómica Avanzada, CINVESTAV-IPN, Libramiento Norte Carretera Irapuato-León Km. 9.6, C.P, 36824, Irapuato, Gto, Mexico. 4. Centro Médico ISSEMyM "Arturo Montiel Rojas", Av. Baja Velocidad No. 284, Carretera México-Toluca Km 57.5, Col. San Jerónimo Chicahualco, C.P. 52170, Metepec, Edo. Mex, Mexico. 5. Departamento de Infectómica y Patogénesis Molecular, CINVESTAV-IPN. Ave. Instituto Politécnico Nacional No. 2508, Col. San Pedro Zacatenco, C.P. 07360, Mexico City, Mexico. ptr@cinvestav.mx.
Abstract
BACKGROUND: Ovarian cancer is the leading cause of mortality among malignant gynecological tumors. Surgical resection and chemotherapy with intravenous platinum/taxanes drugs are the treatments of choice, with little effectiveness in later stages and severe toxicological effects. Therefore, this study aimed to evaluate the antineoplastic activity of gallic acid (GA) and myricetin (Myr) administrated peritumorally in Nu/Nu mice xenotransplanted with SKOV-3 cells. METHODS: Biological activity of GA and MYR was evaluated in SKOV-3 and OVCAR-3 cells (ovarian adenocarcinomas) by confocal/transmission electron microscopy, PI-flow cytometry, H2-DCF-DA stain, MTT, and Annexin V/PI assays. Molecular targets of compounds were determined with ACD/I-Labs and SEA. Antineoplastic activity was performed in SKOV-3 cells subcutaneously xenotransplanted into female Nu/Nu mice treated peritumorally with 50 mg/kg of each compound (2 alternate days/week) for 28 days. Controls used were paclitaxel (5 mg/kg) and 20 μL of vehicle (0.5% DMSO in 1X PBS). Tumor lesions, organs and sera were evaluated with NMR, USG, histopathological, and paraclinical studies. RESULTS: In vitro studies showed a decrease of cell viability with GA and Myr in SKOV-3 (50 and 166 μg/mL) and OVCAR-3 (43 and 94 μg/mL) cells respectively, as well as morphological changes, cell cycle arrest, and apoptosis induction due to ROS generation (p ≤ 0.05, ANOVA). In silico studies suggest that GA and MYR could interact with carbonic anhydrase IX and PI3K, respectively. In vivo studies revealed inhibitory effects on tumor lesions development with GA and MYR up to 50% (p ≤ 0.05, ANOVA), with decreased vascularity, necrotic/fibrotic areas, neoplastic stroma retraction and apoptosis. However, toxicological effects were observed with GA treatment, such as leukocyte infiltrate and hepatic parenchyma loss, hypertransaminasemia (ALT: 150.7 ± 25.60 U/L), and hypoazotemia (urea: 33.4 ± 7.4 mg/dL), due to the development of chronic hepatitis (p ≤ 0.05, ANOVA). CONCLUSION: GA and Myr (50 mg/kg) administered by peritumoral route, inhibit ovarian tumor lesions development in rodents with some toxicological effects. Additional studies will be necessary to find the appropriate therapeutic dose for GA. Therefore, GA and Myr could be considered as a starting point for the development of novel anticancer agents.
BACKGROUND:Ovarian cancer is the leading cause of mortality among malignant gynecological tumors. Surgical resection and chemotherapy with intravenous platinum/taxanes drugs are the treatments of choice, with little effectiveness in later stages and severe toxicological effects. Therefore, this study aimed to evaluate the antineoplastic activity of gallic acid (GA) and myricetin (Myr) administrated peritumorally in Nu/Nu mice xenotransplanted with SKOV-3 cells. METHODS: Biological activity of GA and MYR was evaluated in SKOV-3 and OVCAR-3 cells (ovarian adenocarcinomas) by confocal/transmission electron microscopy, PI-flow cytometry, H2-DCF-DA stain, MTT, and Annexin V/PI assays. Molecular targets of compounds were determined with ACD/I-Labs and SEA. Antineoplastic activity was performed in SKOV-3 cells subcutaneously xenotransplanted into female Nu/Nu mice treated peritumorally with 50 mg/kg of each compound (2 alternate days/week) for 28 days. Controls used were paclitaxel (5 mg/kg) and 20 μL of vehicle (0.5% DMSO in 1X PBS). Tumor lesions, organs and sera were evaluated with NMR, USG, histopathological, and paraclinical studies. RESULTS: In vitro studies showed a decrease of cell viability with GA and Myr in SKOV-3 (50 and 166 μg/mL) and OVCAR-3 (43 and 94 μg/mL) cells respectively, as well as morphological changes, cell cycle arrest, and apoptosis induction due to ROS generation (p ≤ 0.05, ANOVA). In silico studies suggest that GA and MYR could interact with carbonic anhydrase IX and PI3K, respectively. In vivo studies revealed inhibitory effects on tumor lesions development with GA and MYR up to 50% (p ≤ 0.05, ANOVA), with decreased vascularity, necrotic/fibrotic areas, neoplastic stroma retraction and apoptosis. However, toxicological effects were observed with GA treatment, such as leukocyte infiltrate and hepatic parenchyma loss, hypertransaminasemia (ALT: 150.7 ± 25.60 U/L), and hypoazotemia (urea: 33.4 ± 7.4 mg/dL), due to the development of chronic hepatitis (p ≤ 0.05, ANOVA). CONCLUSION: GA and Myr (50 mg/kg) administered by peritumoral route, inhibit ovarian tumor lesions development in rodents with some toxicological effects. Additional studies will be necessary to find the appropriate therapeutic dose for GA. Therefore, GA and Myr could be considered as a starting point for the development of novel anticancer agents.
Authors: Monika B S Oliveira; Iara B Valentim; Tauane S Rocha; Jaqueline C Santos; Keyla S N Pires; Eloiza L L Tanabe; Karen S C Borbely; Alexandre U Borbely; Marília O F Goulart Journal: Ind Crops Prod Date: 2020-04-28 Impact factor: 5.645
Authors: Hugo Varela-Rodríguez; Diana G Abella-Quintana; Annie Espinal-Centeno; Luis Varela-Rodríguez; David Gomez-Zepeda; Juan Caballero-Pérez; Paola L García-Medel; Luis G Brieba; José J Ordaz-Ortiz; Alfredo Cruz-Ramirez Journal: Front Cell Dev Biol Date: 2020-11-19
Authors: Nihal Mostafa; Ahmed Salem; Somaya Z Mansour; Sawsan M El-Sonbaty; Fatma S M Moawed; Eman I Kandil Journal: Technol Cancer Res Treat Date: 2022 Jan-Dec